FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31

Fulcrum Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$3.70+0.05 (+1.37%)

Close on Oct 19, 2026

Market cap: $282.18M
P/E (TTM): –
Dividend yield: –

Fulcrum Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Stock-Based Compensation	12	15	15	13	11	7.35	4.22	2.16
Change in Accounts Receivable	2.10	-1.56	-0.31	0.91	-0.61	0.53	–	–
Change in Accounts Payable	0.43	-1.59	-0.85	-1.18	0.97	1.77	0.80	-0.02
Change in Unearned Revenue	–	0	-0.93	-3.78	-13	7.88	10	–
Operating Cash Flow	-60	-2.22	-91	-97	-78	-54	-39	-23
Capital Expenditures	-0.31	-0.28	-0.51	-1.96	-1.71	-1.34	-0.85	-8.98
Purchase of Investments	-180	-179	-195	-151	-216	-124	–	–
Investing Cash Flow	31	32	-37	12	-130	-57	-0.94	-8.98
Stock Issued	4.17	2.75	0.78	3.52	3.67	1.43	0.25	0.01
Financing Cash Flow	169	2.75	118	84	187	71	64	105
Net Change in Cash	139	33	-9.54	-0.31	-22	-40	24	73
Free Cash Flow	-60	-2.50	-91	-99	-80	-55	-40	-32
Interest Paid	–	–	–	–	0	0.00	0.01	0.01

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -25.3%

Financial strength

Current ratio: 31.35
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 470.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.91
Dividend yield: –